This is a continuation application from the Atlanta Regional Community Clinical Oncology Program (ARCCOP), which was first funded in 1987. The ARCCOP has grown to a consortium of eight hospitals (one component and seven affiliate institutions) that completely surround the Atlanta metropolitan area. Over the past five years, 472 patients have been enrolled in treatment trials and 253 in cancer control studies. The ARCCOP has primarily been successful in accomplishing the specific aims developed for the last proposal: coordinate and expand existing hospital resources; continue operational excellence and active participation among all ARCCOP institutions; meet/surpass clinical treatment protocol accrual; meet/surpass cancer control protocol accrual; collaborate with research bases (SWOG, NSABP, MDACC, RTOG, URCC); refine the data management system; maintain and expand the quality assurance program; maintain investigator standards; increase involvement of primary care physicians; maintain/support strong community cancer programs; disseminate information from NCI and the research bases; and assist the NCI in reducing cancer incidence, morbidity and mortality. Plans for the next funding cycle include continuation of these goals as well as seeking active leadership roles within the ARCCOP research bases and the Association of Community Cancer Centers (ACCC) to facilitate excellence in the clinical trials process and to serve as an active resource for the NCI Clinical Trials Implementation Committee. The ARCCOP was designated as a clinical site for both the Breast Cancer Prevention Trial (BCPT)I and the Prostate Cancer Prevention Trial (PCPT). Over 100 participants were enrolled in each trial by the ARCCOP during the years of accrual. Plans for the immediate future of the ARCCOP include application to be a clinical site for the Study of Raloxifene and Tamoxifen (STAR) trial from NSABP and the next Prostate Cancer Prevention Trial from SWOG. Successful research base audits have proven the ARCCOP quality assurance mechanisms effective and attest to the experience of the investigators and the leadership and organizational skill of the key personnel. Renewed funding will allow this outstanding research program to continue to assist the NCI in reducing cancer incidence, morbidity and mortality by assisting the transfer of new technologies to widespread community application.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA045450-17
Application #
6632889
Study Section
Special Emphasis Panel (ZCA1-SRRB-7 (J4))
Program Officer
Kelaghan, Joseph
Project Start
1987-08-01
Project End
2004-05-31
Budget Start
2003-06-01
Budget End
2004-05-31
Support Year
17
Fiscal Year
2003
Total Cost
$652,311
Indirect Cost
Name
St. Joseph's Hospital
Department
Type
DUNS #
079380481
City
Atlanta
State
GA
Country
United States
Zip Code
30342
West, Howard L; Moon, James; Wozniak, Antoinette J et al. (2018) Paired Phase II Studies of Erlotinib/Bevacizumab for Advanced Bronchioloalveolar Carcinoma or Never Smokers With Advanced Non-Small-cell Lung Cancer: SWOG S0635 and S0636 Trials. Clin Lung Cancer 19:84-92
Hussain, Maha; Tangen, Catherine M; Thompson Jr, Ian M et al. (2018) Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921. J Clin Oncol 36:1498-1504
Heinrich, Michael C; Rankin, Cathryn; Blanke, Charles D et al. (2017) Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033. JAMA Oncol 3:944-952
Durie, Brian G M; Hoering, Antje; Abidi, Muneer H et al. (2017) Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet 389:519-527
Goldkorn, Amir; Ely, Benjamin; Tangen, Catherine M et al. (2015) Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial. Int J Cancer 136:1856-62
Blumenthal, Deborah T; Rankin, Cathryn; Stelzer, Keith J et al. (2015) A Phase III study of radiation therapy (RT) and O?-benzylguanine + BCNU versus RT and BCNU alone and methylation status in newly diagnosed glioblastoma and gliosarcoma: Southwest Oncology Group (SWOG) study S0001. Int J Clin Oncol 20:650-8
Budd, George T; Barlow, William E; Moore, Halle C F et al. (2015) SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. J Clin Oncol 33:58-64
Friedberg, Jonathan W; Unger, Joseph M; Burack, W Richard et al. (2014) R-CHOP with iodine-131 tositumomab consolidation for advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0433. Br J Haematol 166:382-9
Erba, Harry P; Othus, Megan; Walter, Roland B et al. (2014) Four different regimens of farnesyltransferase inhibitor tipifarnib in older, untreated acute myeloid leukemia patients: North American Intergroup Phase II study SWOG S0432. Leuk Res 38:329-33
Carson 3rd, William E; Unger, Joseph M; Sosman, Jeffrey A et al. (2014) Adjuvant vaccine immunotherapy of resected, clinically node-negative melanoma: long-term outcome and impact of HLA class I antigen expression on overall survival. Cancer Immunol Res 2:981-7

Showing the most recent 10 out of 52 publications